drugset / Trial / NCT00760214
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-04
- Completion
- 2009-04
Outcome
Met primary endpoint
registry analysis (superiority or other test); Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD; p <.001; Mean Difference (Final Values) -8.41 (95% CI -11.04 to -5.78) NCT00760214 ↗
registry analysis (superiority or other test); Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD; p <.001; Mean Difference (Final Values) -9.03 (95% CI -11.66 to -6.39) NCT00760214 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azilsartan medoxomil | Other / unclassified | 40 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 80 mg | Oral |
| Comparator | Ramipril | Small molecule | 10 mg | Oral |